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Abstract
The purpose of this case study was to use an evidence based medicine approach to
work through an unusual way of treating a common problem. We looked at an example
of an in-patient with severe refractory psychotic depression who had been resistant to
treatment with a combination of antidepressant, antipsychotics, mood stabiliser, and
concomitant ECT therapy.
We then undertook a literature search for the use of clozapine in a patient with severe
refractory depression.
Although the resulting evidence was low level and thin, we felt on balance that a trial of
clozapine was justified.
We used a BPRS inventory to monitor her mood prior to commencing clozapine. Her
mood and functional abilities were monitored as her clozapine was titrated upwards.
Our patient showed a significant improvement in mood and functional abilities and a
reduction in her BPRS score during this period. Her symptoms improved to the point
where she was successfully discharged home on a combination of clozapine and an
antidepressant.
The improvement was sustained for a further two years.
We thought this was an important case to highlight the limited evidence in using this
successful form of treatment for a common clinical problem and that further research
in this area was needed.
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Background
We present a case study using the Evidence Based Medi-
cine approach and have attempted to work through a
common problem. The aim of the process was to under-
pin our clinical decision with relevant research evidence.
Case
A 39-year-old married housewife with 2 children aged 16
and 12 years was electively admitted for treatment of
worsening depression.
She had a 5-year history of recurrent severe depressive epi-
sodes; there had been no history of mental health prob-
lems prior to this. She had been an in-patient for most of
the last 5 years, and had required one-to-one nursing on
one admission because of self-harming behaviour, which
included cutting and trying to set herself on fire.
She had been raped at the age of 12 years; however, prior
to her first episode of depression she had a well-adjusted
pre-morbid personality, having not had any symptoms
suggestive of post traumatic stress disorder prior to her
history of depression. A diagnosis of post traumatic stress
disorder had been considered, however, rejected because
her depressive affective symptoms dominated her clinical
presentation, and she did not suffer flashbacks to her
index traumatic episode. Other diagnoses that merited
consideration included schizoaffective disorder and bipo-
lar disorder, however, she did not suffer from first rank
symptoms of schizophrenia or hypomanic/manic epi-
sodes which excluded her respectively from both of these
diagnoses according to ICD-10.
The depressive symptoms followed soon after a triggering
event of a horse-riding accident from which she suffered
concussion. A CT scan at the time was reported as normal.
She had a family history of mental disorder, with a sister
who suffered from schizophrenia.
During this present admission she had experienced 5-
month deterioration in mood. She had a 1-week period of
insomnia and increasing suicidal ideation. There was no
history of alcohol/substance misuse or any medical prob-
lems. She had been receiving ECT treatment twice weekly
in the community for the 4 months preceding the admis-
sion. The ECT continued after she was admitted. Her med-
ication was:
Lithium carbonate 1000 mg once daily
Mirtazapine 60 mg at night
Olanzapine 20 mg at night
Chlorpromazine 50 mg at night
On MSE, she had psychomotor retardation with poor eye
contact and a constant rocking motion. Her affect was
melancholic. There was no formal thought or perceptual
disorder, or evidence of cognitive impairment.
On 13/8/01 she was started on a 4-day course of dexame-
thasone, which is an unusual but published treatment for
resistant depression (Dexamethasone augmentation in
treatment resistant depression Acta Psychiatr Scan 1997;
95 58–61). There were no obvious beneficial effects, and
she still felt low in her mood, now with a blunted affect.
Her speech was slower and more monotonous. She had
decreased motivation. She had worsening suicidal idea-
tion.
On 19/8/01 the patient became very agitated and started
lashing out. Several staff members were needed to restrain
her and she was sedated with IM lorazepam. The follow-
ing day she reported hearing voices of her rapists saying
derogatory comments to her.
The patient's mirtazapine, chlorpromazine and olanzap-
ine medication were stopped and she was started on
haloperidol and amitriptyline. Two days later, she started
experiencing second person auditory hallucinations of the
rapist who assaulted her in her childhood. She became
more restless and agitated. Her suicidal ideation increased
and she had difficulty thinking clearly. She continued to
receive ECT treatment and her medication was increased
to 200 mg amitriptyline and 40 mg of haloperidol.
Formulating an Evidence Based Medicine question
We felt it was important to formulate an EBM question
that could be researched in view of possible treatment
approaches that we could offer. We had already tried her
on a variety of medical treatments, which had limited
benefit.
The question formulated was as follows: 'In a patient who
has depression with psychotic symptoms, is the use of clozapine
and an antidepressant more beneficial than standard treat-
ments for psychotic depression, in improving mood and psy-
chotic symptoms.'
Literature search
The literature search that was conducted used the follow-
ing databases:
Cochrane Database, ACP Journal Club, CCTR, 1986–
2002
Medline 1966–2002.Annals of General Psychiatry 2006, 5:20 http://www.annals-general-psychiatry.com/content/5/1/20
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EMBASE 1993–1996.
PSYCHINFO 1887–2002
The manufacturers of clozapine were also contacted.
The keywords used were:
1 'Depression/Depressive disorder/mood disorder/affec-
tive disorder/Psychosis/Psychotic'
2 The above keywords were combined with 'clozapine
and antidepressant agents'.
The search was originally limited to the years 1986–2002,
English language, and human research (however, the lim-
itations were not valid in Cochrane, ACP, DARE, CCTR).
However, an up to date review on the above databases up
to 2006 was conducted on follow up of the patient which
yielded no further pertinent papers.
The original search initially yielded 147 articles but on
further inspection only 8 were thought to be pertinent to
the question. The lists of references for these papers were
also reviewed.
Critically appraising the evidence
As we can see from the table above the evidence is limited.
The only evidence specific for the question is limited to
low-level evidence with only case study/series evidence.
The higher quality evidence is limited by being non-spe-
cific, especially with regards to the case that we are consid-
ering, as the evidence is looking at a heterogeneous
population with conditions including schizophrenia,
bipolar disorder and psychotic depression, often without
comparison groups, and varying outcome measures.
Summary of the evidence
The following evidence [1-3,7] [see table 1], all conducted
retrospective chart/case series that suggested that clozap-
ine was effective in improving affective symptoms, and in
improving psychotic symptoms across a range of diag-
noses from schizophrenia to depression with psychotic
symptoms, however a major limitation to these studies is
that they tended to focus on a heterogeneous population,
with a minority of patients that had depression with psy-
chotic symptoms. There was also a lack of comparison
study groups in these trials.
A randomised prospective trial examining clozapine ver-
sus treatment as usual [4] [see table 1] performed in a
patient population with schizoaffective disorder or bipo-
lar disorder, the results of which suggested that clozapine
had independent mood stabilising effects. However, it did
not have a sub-group of patients with depression with
psychotic symptoms, and therefore it was not suitable for
formulating an answer to our question.
A systematic review [6] [see table 1] of retrospective stud-
ies, open label trials, some of which have been included
in the literature review, showed clozapine was useful in
the short term and maintenance of symptoms of patients
with severe psychotic mood disorders. However, the limi-
tations again were that the trials reviewed had a heteroge-
neous population with outcome measures that varied
according to the trial studied. There was no double blind
comparison trial of clozapine in depression with psy-
chotic symptoms.
Case study and case series [5,8] work show that clozapine
treatment was useful in a select number of cases of refrac-
tory depression with psychotic features that had failed to
respond to conventional treatment including ECT treat-
ment and other neuroleptic medication. This was very
specific to the case that we were studying, however, the
evidence was at a low level in the hierarchy.
Intervention
Although the evidence is thin, our patient's symptoms
were severe and other treatment for depression had failed.
On balance, we felt that a trial of clozapine was justified.
On 7/9/01 after a discussion with her and her husband,
including an explanation that clozapine treatment, would
be used outside its license, it was decided that she should
commence clozapine. Other medication at the time was
(daily dose):
Amitriptyline 200 mg
Haloperidol 40 mg
Lithium 1000 mg
Haloperidol was decreased, ECT treatment was stopped
and clozapine was started on the 28/9/01, and gradually
titrated upwards monitoring her mental state and side
effects.
A BPRS rating scale performed four days prior to com-
mencing on clozapine was 63. She had marked decrease
in emotional contact, very confused thought processes,
visible nervousness and tension. Her mood was very low;
she had gross psychomotor retardation and a blunted
affect.
Over the subsequent few weeks she continued experienc-
ing low mood, ongoing suicidal ideation, and more con-
fusion and had difficulty completing sentences. She
experienced difficulty waking up and problems with her
short-term memory.A
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Table 1: Key Papers identified from the literature search
Author Date Description Type of Study Outcome Limitations
McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, 
Frankenberg FR, Aizley HG, O'Brien S [1]
1991 Clozapine in the treatment of 
Psychotic mood disorders, 
schizoaffective disorder and 
schizophrenia.
Retrospective Chart analysis of 
patients with 39 schizophrenia, 
25 schizoaffective disorder and 
14 bipolar disorder with 
psychotic features
Clozapine was shown to be useful in 
the treatment of patients with 
schizoaffective disorder or psychotic 
mood disorder who are treatment 
resistant or intolerant of side effects.
There was no standardisation 
of treatment given prior to 
clozapine administration. There 
was no comparison group or 
long term follow up of patients.
Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, 
Kolbrener M, Kim JW, Cole JO. [2]
1994 Clozapine therapy in refractory 
affective disorders: polarity 
predicts response in long-term 
follow up.
Retrospective Review of 193 
Case Notes of 52 Bipolar 
Disorder, 81 schizoaffective 
disorder, 14 unipolar 
depression, 40 schizophrenia, 
and 6 other disorder.
Clozapine is an efficacious and well-
tolerated therapy for refractory 
affective illness. Manic symptomatology 
predicts a more favourable response 
than depression.
Heterogeneous groups studied, 
not standardised for 
demographics, no comparison 
group for treatment with 
clozapine, no knowledge of 
prior treatment given.
Collaborative Working Group on Clinical Trial Evaluations.[3] 1998 Evaluating the usefulness of 
atypical antipsychotics in 
reducing suicidality in 
schizophrenic patients and their 
use in affective disorders
Review Atypical antipsychotics may be used as 
an adjunctive medication or an 
alternative to mood stabilizers in 
patients with affective disorders
Not specific to clozapine and 
not evaluating controlled trials.
Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush 
AJ.[4]
1999 Clinical Outcome in a 
Randomised 1 year trial of 
Clozapine versus treatment as 
usual for patients with 
treatment resistant illness and a 
history of mania
Prospective randomised trial 38 
patients with schizoaffective 
disorder and bipolar disorder.
Showed that clozapine had independent 
mood stabilising properties.
Looks at heterogeneous 
population of Not specific to 
psychotic depression.
Ranjan R, Meltzer HY.[5] 1996 Acute and Long term 
Effectiveness of Clozapine in 
treatment -resistant psychotic 
depression
Case Series Only 3 cases 
studied.
In all 3 cases, clozapine treatment was 
associated with significant improvement 
in both affective and psychotic 
symptoms. Maintenance in remission 
was sustained over many years
Only 3 cases studied, there was 
no comparison group.
Zarate CA Jr, Tohen M, Baldessarini RJ.[6] 1995 Clozapine in Severe Mood 
Disorders.
Systematic Review Clozapine appears to be effective and 
well tolerated in the short term and 
maintenance of severe or psychotic 
mood disorders.
Heterogeneous analysis of 
different trials including case 
series, retrospective analysis 
and open label trials. No double 
blind studies specific to the 
treatment with clozapine. 
Outcome measures varied 
according to the trial used.
Naber D, Holzbach R, Perro C, Hippius H.[7] 1992 Clinical Management of 
Clozapine Patients in Relation 
to Efficacay and Side-Effects.
Retrospective analysis of 644 
medical charts, patients who 
were given clozapine after 
standard neuroleptic treatment 
had failed.
Efficacy of clozapine was satisfactory in 
55–72% of patients with organic 
psychosis, mania, psychotic depression 
or Parkinson's disease.
Majority of patients had 
schizophrenia and 
schizoaffective disorder only 54 
had psychotic depression. The 
study tended to focus on the 
side effect profile of clozapine in 
schizophrenia
Dassa D, Kaladjian A, Azorin JM, Giudicelli S.[8] 1993 Clozapine in the Treatment of 
Psychotic Refractory 
Depression.
Case Study Depressive and psychotic features 
improved after the administration of 
clozapine suggesting that clozapine 
could be efficient in psychotic 
refractory depression
Only one case studied.Annals of General Psychiatry 2006, 5:20 http://www.annals-general-psychiatry.com/content/5/1/20
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Four weeks later the BPRS score was 39. She was less emo-
tionally withdrawn and was interacting better with those
around her. She was improved in mood, her affect was
more reactive and there was considerable improvement in
her psychomotor functioning. She still exhibited some
thought confusion and showed less physical tension and
nervousness. She was now experiencing somatic halluci-
nations of someone touching her but the auditory hallu-
cinations were less intense.
She continued to improve and was now able to go on
some home leave with her husband. Two months after
starting clozapine there was a global improvement in her
BPRS 33 [see figure 1], however, she still appeared low in
her mood. However, she experienced hypersalivation and
her amitryptiline was increased because of its antimus-
carininic effects. She was sleeping well with no difficulties
getting up in the morning and there was less suicidal ide-
ation.
After four months of clozapine treatment, her BPRS score
was 21 [see figure 1] and she scored minimally on all cri-
teria measured. She was now having extended periods of
home leave on her own and was able to laugh and joke
with other staff members. She no longer experienced any
somatic/auditory hallucinations. She was able to resume
other activities at home including domestic duties and
shopping.
Conclusion
The evidence based medicine approach provides a frame-
work with which to use evidence to support clinical prac-
tice. It guides the clinician in making a decision about
treatment. However, with regard to the question that was
asked, the evidence supporting use of clozapine was rather
limited. The approach allows clinicians to use relatively
weak evidence with other clinical skills. It necessitates the
use of innovative practice at times, and enables clinicians
to contribute to research ideas and development. EBM
reviews such as this may contribute to further research
ideas.
In this case clozapine made a significant improvement in
clinical state. There were many uncontrolled factors that
Figure 1
BPRS Following introduction of Clozapine
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could have contributed to the overall improvement but in
this patient the resistance to all previous treatments sug-
gests that clozapine use was responsible for the improve-
ment. It could be argued that the use of amitriptyline
could have contributed; however, it had been used on sev-
eral previous occasions with no benefit.
We thought it would be interesting to follow up the
patient to see if the benefits of clozapine treatment were
sustained. The patient had an admission for another
depressive episode almost two years later, and was then
discharged on clozapine 150 mg in the morning and 300
mg at night. She was subsequently reviewed in the outpa-
tient clinic regularly and has remained well.
Another literature search (of the same original databases)
yielded no further evidence supporting the use of clozap-
ine in depression with psychotic symptoms, other than a
single case report [9] which described a case of a 48 year
old woman with refractory depression who responded
well to a combination of clozapine and maprotilline after
ECT and other antidepressants failed to work, however
this did not address our question as the case did not have
psychotic symptoms.
Referring back to the original question 'In a patient with
depression with psychotic symptoms, is the long term use of cloz-
apine and antidepressant more beneficial than standard, sec-
ond and third line treatment for psychotic depression, in
improving mood and psychotic symptoms', there remains
much uncertainty and we would support further research
in this area, allowing us to give more than a reserved and
qualified affirmation.
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